A new UCLA study
found Unfold AI's precise prediction of prostate margins
significantly impacts the success of focal therapy
treatments
CULVER
CITY, Calif., May 8, 2024
/PRNewswire/ -- Avenda Health, an AI healthcare company
creating the future of personalized prostate cancer care, unveils
the results of a new UCLA study
examining the role of AI in identifying tumor margins and
predicting the efficacy of focal therapy treatments. The study
titled "Software to Determine Extent of Tumor Margins in Focal
Therapy," was presented at the 2024 American Urological
Association's (AUA) annual meeting by Wayne
Brisbane, MD, assistant professor at UCLA Health. It
demonstrated that Unfold AI, Avenda Health's AI-powered cancer
mapping technology, was a better predictor of focal therapy success
than other factors, including the size or grade of the tumor.
In the study, FDA-cleared Unfold AI technology was
retrospectively applied to 118 previously untreated men undergoing
hemi-gland cryotherapy for prostate cancer ablation. MRI-guided
biopsies, both targeted and systematic, were performed before
cryotherapy and six months after cryotherapy to assess treatment
outcomes. The study found that the baseline Gleason Grade Group
(GG), which categorizes the aggressiveness of prostate cancer (GG1
indicating low-grade and GG5 high-grade), consisted of 66.8% GG2,
28% GG3, and 5.3% GG4. Treatment success, defined as the absence of
>GG2 on post-cryotherapy MRI-guided biopsies, was achieved in
77.7% of cases and was not found to be correlated with baseline
GG.
The study found that Unfold AI's patient-specific encapsulation
confidence score (ECS), which is generated based on multiple
patient data points, including MRI scans, biopsy results, PSA data
and Gleason scores, is critical for predicting treatment success.
While factors like cancer core length, the percentage of Gleason
pattern 4, and ECS score were predictive of treatment success, only
an ECS score greater than or equal to 0.7 demonstrated significant
predictive value, with a success rate of 70% (confidence interval:
61-79%) and 68% (confidence interval: 51-85%), respectively. These
findings emphasize the importance of Unfold AI's assessment of
tumor margins in predicting treatment outcomes, surpassing the
predictive capability of conventional parameters.
The study's findings hold important implications for clinical
practice, suggesting that Unfold AI's ECS score could revolutionize
treatment decision-making for prostate cancer patients. By
increasing confidence in predicting tumor margins, Unfold AI
empowers physicians to tailor interventions more effectively to
individual patient needs, potentially improving treatment outcomes
and quality of life.
"Unfold AI's ability to identify tumor margins and provide the
ECS will improve treatment recommendations and allow for
less-invasive interventions," said Dr. Wayne Brisbane. "This more comprehensive
approach enhances our ability to predict treatment outcomes and
tailor interventions effectively to individual patient needs."
"These results demonstrate a marked change in how physicians
will be able to diagnose and recommend treatment for prostate
cancer patients," said Avenda Health CEO Shyam Natarajan, PhD. "By increasing the
confidence in which we can predict a tumor's margins, patients and
their doctors will have increased certainty that their entire tumor
is treated and with the appropriate intervention in correlation to
the severity of their case."
For more information, visit avendahealth.com.
About Avenda Health
Avenda Health is creating a more
personalized future of prostate cancer care. Using deep
learning, Avenda Health software maps a patient's cancer in 3D,
giving physicians precise information and the confidence to make
care decisions. Dedicated to bringing this cutting-edge
technology to all practices and physicians treating prostate cancer
patients, Avenda Health aims to improve outcomes, preserve quality
of life, and create a new standard of cancer care.
For more information, visit avendahealth.com and follow the
company on LinkedIn and Twitter.
View original
content:https://www.prnewswire.com/news-releases/new-study-demonstrates-avenda-healths-unfold-ai-to-better-predict-focal-therapy-success-by-77-percent-as-compared-to-standard-methods-302140020.html
SOURCE Avenda Health